Praxis Precision Medicines, Inc. PRAX Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Xenon PharmaceuticalsXENE

$1.34M-8.3%

Stoke Therapeutics, Inc.STOK

$2.43M+3.5%

Rapport Therapeutics, Inc.RAPP

$2.47M+40.6%

Neurocrine BiosciencesNBIX

$57.3M+25.7%

MapLight Therapeutics, Inc.MPLT

$920K—

FAQ

What is Praxis Precision Medicines, Inc.'s operating lease liabilities (current)?

Praxis Precision Medicines, Inc. (PRAX) reported operating lease liabilities (current) of $1.09M in Q2 2026.

How has Praxis Precision Medicines, Inc.'s operating lease liabilities (current) changed year-over-year?

Praxis Precision Medicines, Inc.'s operating lease liabilities (current) increased by 44.0% year-over-year, from $755K to $1.09M.

What is the long-term trend for Praxis Precision Medicines, Inc.'s operating lease liabilities (current)?

Over 5 years (2020 to 2025), Praxis Precision Medicines, Inc.'s operating lease liabilities (current) has grown at a -32.1% compound annual growth rate (CAGR), from $763K to $110K.

What does operating lease liabilities (current) mean?

The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.